IND
Interim New Drug – A submission to the FDA that discloses the manufacturing procedure and all required testing. FDA reviews IND’s in 30-60 days.
Tag: FDA
NCTR
National Center for Toxicological Research
NDA or ANDA
New Drug Application – Required prior to offering a new drug to market Abbreviated New Drug Application – Used for the submission of a generic drug application to the FDA
Validation
Confirming that the outcome is repeatable and is what as expected.